Medication info
Candecan Duo Tablet 20/32 mg

Candecan Duo Tablet 20/32 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletCandesartan Cilexetil›32mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Pink, round film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP X 3]
Approval status
Active

MFDS item code 202107122 · Approved 2021.10.25 · Insurance code 694003690

Summary

Main use
Treatment of hypertension and heart failure, improvement of dyslipidemia, inhibition of atherosclerosis progression and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. Elderly patients: No adjustment of the initial dose is necessary. Patients with intravascular volume depletion: In patients at increased risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or more and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Essential hypertension: Children: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. Heart failure: Children: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure, improvement of dyslipidemia, inhibition of atherosclerosis progression and cardiovascular risk

  • Essential hypertension
  • heart failure
  • impairment of left ventricular systolic function
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • abnormal beta-lipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
View approved original text

This medication is used for patients who require both components, Candesartan Cilexetil and Rosuvastatin. Candesartan Cilexetil is primarily used for the treatment of essential hypertension and in cases of heart failure when additional ACE inhibitor therapy is needed or when it is not tolerated well. Rosuvastatin serves as an adjunct to dietary therapy for various dyslipidemias including primary hypercholesterolemia, mixed dyslipidemia, homozygous familial hypercholesterolemia, and abnormal beta-lipoproteinemia. Furthermore, Rosuvastatin helps reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in patients at high risk for cardiovascular diseases. Therefore, this medication is used to improve cardiovascular health by controlling blood pressure and lipid levels.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. Elderly patients: No adjustment of the initial dose is necessary. Patients with intravascular volume depletion: In patients at increased risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or more and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Essential hypertension: Children: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. Heart failure: Children: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially during the second and third trimesters; therefore, it should be discontinued immediately if pregnancy is confirmed. Patients with hypersensitivity to this medication or those with a history of liver disease, severe renal impairment, myopathy, or angioedema should not take this medication. Women of childbearing potential should use appropriate contraceptive measures considering the possibility of pregnancy, and this medication should not be taken if planning to become pregnant or if already pregnant. Special caution is needed when used in elderly patients, those with hyperkalemia, liver disease, and heart disease. This medication can cause muscle-related side effects, such as myalgia and myopathy, and if symptoms like muscle pain or weakness occur, the patient should consult a physician immediately. Liver function abnormalities may occur, so regular liver function tests are recommended before and during treatment. This medication may interact with other drugs, and any other medications being taken should be reported to the healthcare provider. Care should be taken, especially when used in conjunction with potassium-sparing diuretics, lithium, or nonsteroidal anti-inflammatory drugs (NSAIDs). In case of overdose, appropriate treatment is required based on the symptoms, and this medication is not removed by dialysis. Caution is advised for dizziness or fatigue when driving or operating machinery. Keep this medication out of the reach of children, and it is safer not to transfer medicines from their original container to another container.

Side effects

Headache, nasopharyngitis, localized infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, elevated blood sugar, decreased blood sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, headache, itching, nausea, dizziness, orthostatic dizziness, miliaria, periodontitis, inflammation, foreign body sensation, cataract, musculoskeletal pain, neck pain, chest discomfort, tooth extraction, elevated blood sugar, decreased blood sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, fever, paresthesia, dyspepsia, gastroenteritis, tachycardia, palpitations, hyperglycemia, hypertriglyceridemia, hyperuricemia, epistaxis, anxiety, depression, drowsiness, dyspnea, hematuria, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, edema, sleep disorders, decreased libido, amnesia, anorexia, increased appetite, tinnitus, gustatory disturbance, erectile dysfunction, paralysis, hypertonia, syncope, facial flushing, facial edema, thirst, arthralgia, numbness, sensory disturbance, chest discomfort, abdominal pain, diarrhea, anorexia, abdominal distension, syncope, generalized pain, muscle cramping, gout, acute kidney failure, oliguria, thrombocytopenia, increased blood creatinine, hypotension, hyperkalemia, kidney function impairment, increased creatinine, increased urea, increased potassium, decreased sodium, elevated ALT, dizziness, low back pain, respiratory infection, upper respiratory infection, pharyngitis, rhinitis, fatigue, peripheral edema, chest pain, bronchitis, cough, sinusitis, nausea, abdominal pain, diarrhea, vomiting, arthralgia, proteinuria, weakness, fever, paresthesia, dizziness, dyspepsia, gastroenteritis, tachycardia, palpitations, hyperglycemia, hypertriglyceridemia, hyperuricemia, myalgia, epistaxis, anxiety, depression, drowsiness, dyspnea, rash, urticaria, hematuria, increased blood pressure, cerebral infarction, spondyloarthritis myelopathy, musculoskeletal discomfort, pneumonia, femoral fracture, contusion, unstable angina, idiopathic pulmonary fibrosis, wet cough, worsening hypertension, unstable blood pressure, vertigo, orthostatic vertigo, adrenal insufficiency, shock, syncope, loss of consciousness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication can deteriorate due to air or moisture, so it must be stored in a tightly sealed container. It is important to maintain storage temperatures between 1 and 30 degrees Celsius. This helps to preserve the drug's effectiveness and safety over time.

Appearance and packaging

Appearance

Pink, round film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP X 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.